公开(公告)号：US20190321483A1

公开(公告)日：2019-10-24

申请号：US16470897

申请日：2017-12-19

Applicant: NOVARTIS AG

Inventor： Ben WEN ,  Anthony E. BOITANO ,  Matthew BURGER ,  Susan E. CELLITTI ,  Michael P. COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Yunho JIN ,  Si Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO

IPC: A61K47/68 ,  C07K16/28 ,  A61K38/07 ,  A61K38/12

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20220305134A1

公开(公告)日：2022-09-29

申请号：US17833077

申请日：2022-06-06

Applicant: Novartis AG

Inventor： Anthony Edward BOITANO ,  Matthew BURGER ,  Susan E. CELLITTI ,  Michael P. COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Yunho JIN ,  Si Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO ,  Ben WEN

IPC: A61K47/68 ,  A61K38/07 ,  A61K38/12 ,  C07K16/28

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20150336960A1

公开(公告)日：2015-11-26

申请号：US14651996

申请日：2013-12-07

Applicant: Matthew BURGER ,  Gisele NISHIGUCHI ,  Alice RICO ,  Benjamin TAFT ,  NOVARTIS AG

Inventor： Matthew BURGER ,  Gisele NISHIGUCHI ,  Alice RICO ,  Benjamin TAFT

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/5025

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

Abstract translation: 本发明提供本文所述的式（I）化合物及其药学上可接受的盐，对映异构体，旋转异构体，互变异构体或外消旋物。 还提供了使用式（I）的化合物治疗由PIM激酶介导的疾病或病症的方法和包含这些化合物的药物组合物。